Kim C. Ohaegbulam

Kim C. Ohaegbulam

Auto-generated profile, based on publicly available information

Kim C. Ohaegbulam

Department of Radiation Medicine, Oregon Health & Science University, Portland, USA

Research Focus & Metrics

Academic Career Length

7Years (2020-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
16 November 2022 in Cancer
Verified
Journal Article
Closed access
KOKim C. Ohaegbulam
Kim C. Ohaegbulam
YKYilun Koethe
Yilun Koethe
AFAlice Fung
Alice Fung
SMSkye C. Mayo
Skye C. Mayo
AGAaron J Grossberg
Aaron J Grossberg
NNNima Nabavizadeh
Nima Nabavizadeh

4 March 2020 in The Journal of Maternal-Fetal & Neonatal Medicine
Verified
Journal Article
Closed access
JBJeffrey Bernstein
Jeffrey Bernstein
YSYelena Spitzer
Yelena Spitzer
KOKim Ohaegbulam
Kim Ohaegbulam
SRShamantha Reddy
Shamantha Reddy
JSJing Song
Jing Song
SNSingh Nair
Singh Nair
The rate of cesarean delivery is on the rise in the USA. Satisfactory postoperative analgesia remains a top priority for cesarean delivery. Multimodal analgesia with a reduction in opioid consumpti...

29 May 2025 in Advances in Therapy
Verified
Journal Article
Open access
PDF file
YKYongJin Kim
YongJin Kim
YZYong Zhu
Yong Zhu
KMKristin J. Moore
Kristin J. Moore
MDMary DuCharme
Mary DuCharme
DJDan James
Dan James
KOKim Ohaegbulam
Kim Ohaegbulam
Introduction Among patients with unresectable stage III non-small cell lung cancer (NSCLC), those whose tumors harbor epidermal growth factor receptor mutations (EGFRm) are associated with comparatively fewer treatment options and worse prognosis. With the recent approval of targeted treatment, characterizing the economic burden and EGFRm testing and provider referral patterns is crucial to understanding the unmet needs of these patients. Methods This was a retrospective analysis of Optum’s Market Clarity Dataset from January 1, 2018 to June 30, 2023. Eligibility criteria included diagnosis with unresectable stage III EGFRm NSCLC and chemoradiotherapy (CRT) initiation (index date) within 90 days. Primary outcomes were per patient per month (PPPM) all-cause and NSCLC-related health care resource utilization (HCRU) and costs, and EGFRm testing and provider referral patterns. Results A total of 144 patients were followed for a median of 15.5 months; 56.3% of patients underwent EGFRm testing before CRT initiation. All-cause and NSCLC-related costs during follow-up were $28,020 and $22,816 PPPM, respectively. Ambulatory utilization was the major driver of this economic burden. Pharmacy costs accounted for $4244 (15.1%) and $3736 (16.4%) of the total all-cause and NSCLC-related costs, respectively. Between diagnosis and CRT initiation, the most common specialties visited were oncology/hematology (seen by 67.4% of patients), radiology (26.4%), pulmonology (22.2%), and cardiology (21.5%). Patients who visited three or more specialties on separate days before CRT initiation had a median time to CRT initiation of 33.0 days versus 22.0 days when patients visited multiple specialties on the same day (suggestive of a multidisciplinary care team, MDT). Conclusion Patients with unresectable stage III EGFRm NSCLC incur substantial economic burden, especially in ambulatory HCRU and costs. With the recent approval of targeted treatment for these patients, reflex EGFRm testing in all early-stage NSCLC at diagnosis is encouraged. Our results also suggest MDT involvement may improve completeness in diagnosis and staging, resulting in acceleration of treatment planning and management.

12 April 2022 in International Journal of Radiation Oncology - Biology - Physics (IJROBP)
Verified
Journal Article
Closed access
KOKim C. Ohaegbulam
Kim C. Ohaegbulam
RCRavi A. Chandra
Ravi A. Chandra